¾È³çÇϼ¼¿ä ö±ÕÀÔ´Ï´Ù.
À̹øÁÖ Åä¿äÀÏ¿¡ ¹ßÇ¥ÇÒ ³í¹®ÀÇ Á¦¸ñÀº
"CD103+ cDC1 and endogenous CD8+ Tcells are necessary for improved CD40L-overexpressing CAR T cell antitumor function"
À̸ç ÀÛ³â 12¿ù¿¡ nature communication¿¡ ÃâÆǵǾú½À´Ï´Ù.
ÀÌÀü¿¡ ÀúÀÚ°¡ Cancer cell¿¡ º¸°í ÇÑ CD40L-overexpressing CAR T cellÀÇ ¶Ù¾î³ Ç×¾Ï È¿°ú°¡ CAR T cell ÀÚü°¡ °®´Â tumor¸¦ °ø°ÝÇÏ´Â ´É·Â°ú ´õºÒ¾î
°³Ã¼ÀÇ ³»ÀÇ cDC1 °ú CD8+ T cell ÀÇ ºÐÆ÷¿Í È°¼ºÀ» Á¶ÀýÇÑ´Ù´Â ¿¬±¸³»¿ëÀÔ´Ï´Ù.
in-vivo DCsµéÀÇ population°ú surface markerÀÇ º¯È¸¦ È®ÀÎÇϱâ À§ÇÑ ½ÇÇèµé¿¡¼ Âü°í ÇÒ ¼öÀÖ´Â ºÎºÐµéÀÌ ¸¹¾Æ ¼±Á¤ÇÏ°Ô µÇ¾ú½À´Ï´Ù.
Åä¿äÀÏ¿¡ ºË°Ú½À´Ï´Ù.
³í¹® ¸µÅ© : https://www.nature.com/articles/s41467-020-19833-3